IGM BIOSCIENCES INC (IGMS) Stock Price, Forecast & Analysis
USA - NASDAQ:IGMS - US4495851085 - Common Stock
IGMS Key Statistics, Chart & Performance
The current stock price of IGMS is 1.27 USD. In the past year, price decreased by -86.12%.
IGMS Latest News, Press Relases and Analysis
IGMS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.19 | 387.16B | ||
| AMGN | AMGEN INC | 14.64 | 172.38B | ||
| GILD | GILEAD SCIENCES INC | 14.51 | 147.46B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.59 | 104.98B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.61 | 69.69B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 868.04 | 58.03B | ||
| INSM | INSMED INC | N/A | 40.10B | ||
| NTRA | NATERA INC | N/A | 27.39B | ||
| BIIB | BIOGEN INC | 9.29 | 22.80B | ||
| INCY | INCYTE CORP | 16.51 | 20.70B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.01 | 20.30B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 36.45 | 15.11B |
Related stock screener links
About IGMS
Company Profile
IGM Biosciences, Inc. operates as a biotechnology company, which develops antibodies for the treatment of cancer. The company is headquartered in Mountain View, California and currently employs 149 full-time employees. The company went IPO on 2019-09-18. The firm is engaged in developing and delivering a new class of medicines to treat patients with cancer and autoimmune and inflammatory diseases. The Company’s pipeline of clinical and preclinical assets is based on the IgM antibody, which has 10 binding sites compared to conventional IgG antibodies with only two binding sites. The company is also focused on creating, developing, manufacturing, and commercializing IgM antibody agonists against oncology and immunology and inflammation targets. The Company’s development programs include Aplitabart, Imvotamab, and IGM-2644. Aplitabart is an IgM antibody targeting Death Receptor 5 (DR5) proteins, being evaluated in multiple phase I combination trials for the treatment of colorectal cancer. Imvotamab is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins. IGM-2644 is a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins.
Company Info
IGM BIOSCIENCES INC
325 E Middlefield Rd
Mountain View CALIFORNIA 94043 US
CEO: Fred Schwarzer
Employees: 149
Phone: 16509657873
IGM BIOSCIENCES INC / IGMS FAQ
Can you describe the business of IGM BIOSCIENCES INC?
IGM Biosciences, Inc. operates as a biotechnology company, which develops antibodies for the treatment of cancer. The company is headquartered in Mountain View, California and currently employs 149 full-time employees. The company went IPO on 2019-09-18. The firm is engaged in developing and delivering a new class of medicines to treat patients with cancer and autoimmune and inflammatory diseases. The Company’s pipeline of clinical and preclinical assets is based on the IgM antibody, which has 10 binding sites compared to conventional IgG antibodies with only two binding sites. The company is also focused on creating, developing, manufacturing, and commercializing IgM antibody agonists against oncology and immunology and inflammation targets. The Company’s development programs include Aplitabart, Imvotamab, and IGM-2644. Aplitabart is an IgM antibody targeting Death Receptor 5 (DR5) proteins, being evaluated in multiple phase I combination trials for the treatment of colorectal cancer. Imvotamab is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins. IGM-2644 is a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins.
What is the current price of IGMS stock?
The current stock price of IGMS is 1.27 USD. The price decreased by -2.31% in the last trading session.
Does IGM BIOSCIENCES INC pay dividends?
IGMS does not pay a dividend.
How is the ChartMill rating for IGM BIOSCIENCES INC?
IGMS has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Where is IGM BIOSCIENCES INC (IGMS) stock traded?
IGMS stock is listed on the Nasdaq exchange.
What is IGM BIOSCIENCES INC worth?
IGM BIOSCIENCES INC (IGMS) has a market capitalization of 76.57M USD. This makes IGMS a Micro Cap stock.
Can you provide the ownership details for IGMS stock?
You can find the ownership structure of IGM BIOSCIENCES INC (IGMS) on the Ownership tab.
IGMS Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to IGMS. When comparing the yearly performance of all stocks, IGMS is a bad performer in the overall market: 95.57% of all stocks are doing better.
IGMS Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to IGMS. While IGMS has a great health rating, there are worries on its profitability.
IGMS Financial Highlights
Over the last trailing twelve months IGMS reported a non-GAAP Earnings per Share(EPS) of -0.55. The EPS increased by 85.01% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -49.53% | ||
| ROE | -52.48% | ||
| Debt/Equity | 0 |
IGMS Forecast & Estimates
9 analysts have analysed IGMS and the average price target is 1.27 USD. This implies a price increase of 0.39% is expected in the next year compared to the current price of 1.27.
For the next year, analysts expect an EPS growth of 59.87% and a revenue growth 249.45% for IGMS